{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:44:50Z","timestamp":1791308690966,"version":"4.3.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1 TR002380"],"award-info":[{"award-number":["TL1 TR002380"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI143882"],"award-info":[{"award-number":["K23AI143882"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40262-026-01618-4","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:27:33Z","timestamp":1769650053000},"page":"465-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-2397","authenticated-orcid":false,"given":"Zachary L.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin F.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kianoush B.","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"14","key":"1618_CR1","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","volume":"122","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013;122(14):2318\u201330.","journal-title":"Blood"},{"issue":"3","key":"1618_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjh.15661","volume":"184","author":"CP Fox","year":"2019","unstructured":"Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B\u2010cell lymphoma. Br J Haematol. 2019;184(3):348\u201363.","journal-title":"Br J Haematol"},{"issue":"1","key":"1618_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","volume":"25","author":"K Hoang-Xuan","year":"2023","unstructured":"Hoang-Xuan K, Deckert M, Ferreri AJM, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2023;25(1):37\u201353.","journal-title":"Neuro Oncol"},{"issue":"8","key":"1618_CR4","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1172\/JCI107362","volume":"52","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Investig. 1973;52(8):1804\u201311.","journal-title":"J Clin Investig"},{"issue":"4","key":"1618_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","volume":"16","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1618_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.2021012888","volume":"139","author":"VM Orellana-Noia","year":"2022","unstructured":"Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413\u201323.","journal-title":"Blood"},{"issue":"6","key":"1618_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","volume":"21","author":"T Batchelor","year":"2003","unstructured":"Batchelor T, Carson K, O\u2019Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96\u201307. J Clin Oncol. 2003;21(6):1044\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1618_CR8","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283\u201390.","journal-title":"Cancer"},{"issue":"4","key":"1618_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/ijh-2017-0020","volume":"6","author":"SJ Nagle","year":"2017","unstructured":"Nagle SJ, Shah NN, Ganetsky A, et al. Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. Int J Hematol Oncol. 2017;6(4):113\u201321.","journal-title":"Int J Hematol Oncol"},{"issue":"2","key":"1618_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/bloodadvances.2021005999","volume":"6","author":"M Fleming","year":"2022","unstructured":"Fleming M, Huang Y, Dotson E, et al. Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood Adv. 2022;6(2):460\u201372.","journal-title":"Blood Adv"},{"issue":"12","key":"1618_CR11","doi-asserted-by":"publisher","first-page":"e1908","DOI":"10.1200\/OP.22.00182","volume":"18","author":"DF O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue DF, Truong HL, Finnes HD, et al. High-dose methotrexate in patients with lymphoma: predictors of a complicated course. JCO Oncol Pract. 2022;18(12):e1908\u201317.","journal-title":"JCO Oncol Pract."},{"issue":"4","key":"1618_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","volume":"102","author":"M Joerger","year":"2010","unstructured":"Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic\u2013pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102(4):673\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"1618_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90(2):353\u20138.","journal-title":"Br J Cancer"},{"issue":"8","key":"1618_CR14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00277-012-1441-2","volume":"91","author":"B Kasenda","year":"2012","unstructured":"Kasenda B, Rehberg M, Thurmann P, et al. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Ann Hematol. 2012;91(8):1257\u201364.","journal-title":"Ann Hematol"},{"issue":"1","key":"1618_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2017","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high\u2010dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2017;23(1):52\u201361.","journal-title":"Oncologist"},{"issue":"2","key":"1618_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","volume":"4","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4(2):87\u2013101.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1618_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1586\/14737175.6.5.635","volume":"6","author":"MR Green","year":"2006","unstructured":"Green MR, Chowdhary S, Lombardi KM, et al. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother. 2006;6(5):635\u201352.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"1618_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0b013e31823615e1","volume":"33","author":"AM Johansson","year":"2011","unstructured":"Johansson AM, Hill N, Perisoglou M, et al. A population pharmacokinetic\/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit. 2011;33(6):711\u20138.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1618_CR19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00280-006-0202-0","volume":"58","author":"DW Faltaos","year":"2006","unstructured":"Faltaos DW, Hulot JS, Urien S, et al. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol. 2006;58(5):626\u201333.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1618_CR20","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","volume":"34","author":"IW Kim","year":"2012","unstructured":"Kim IW, Yun HY, Choi B, et al. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. Clin Ther. 2012;34(8):1816\u201326.","journal-title":"Clin Ther"},{"issue":"2","key":"1618_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/FTD.0000000000000381","volume":"39","author":"JB Woillard","year":"2017","unstructured":"Woillard JB, Debord J, Benz-de-Bretagne I, et al. A time-dependent model describes methotrexate elimination and supports dynamic modification of MRP2\/ABCC2 activity. Ther Drug Monit. 2017;39(2):145\u201356.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1618_CR22","first-page":"635","volume":"14","author":"N Lameire","year":"2008","unstructured":"Lameire N, Van Biesen W, Vanholder R. Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care. 2008;14(6):635\u201346.","journal-title":"Curr Opin Crit Care"},{"issue":"6","key":"1618_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","volume":"55","author":"J May","year":"2014","unstructured":"May J, Carson KR, Butler S, et al. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma. 2014;55(6):1345\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1618_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/cpt.3493","volume":"117","author":"BA Stottlemyer","year":"2025","unstructured":"Stottlemyer BA, Tran T, Suh K, et al. A systematic review of the costs of drug-associated acute kidney injury and potential cost savings with nephrotoxin stewardship prevention strategies. Clin Pharmacol Ther. 2025;117(4):989\u20131004.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1618_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00280-002-0511-x","volume":"50","author":"JC Panetta","year":"2002","unstructured":"Panetta JC, Yanishevski Y, Pui CH, et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2002;50(5):419\u201328.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1618_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","volume":"42","author":"A Nader","year":"2017","unstructured":"Nader A, Zahran N, Alshammaa A, et al. Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokinet. 2017;42(2):221\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"1618_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139.","journal-title":"N Engl J Med"},{"issue":"19","key":"1618_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"1","key":"1618_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8010035","volume":"8","author":"HR Teaford","year":"2020","unstructured":"Teaford HR, Barreto JN, Vollmer KJ, et al. Cystatin C: a primer for pharmacists. Pharmacy Basel. 2020;8(1):35.","journal-title":"Pharmacy Basel"},{"issue":"1","key":"1618_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12882-020-02165-1","volume":"21","author":"S Liang","year":"2020","unstructured":"Liang S, Shi M, Bai Y, et al. The effect of glucocorticoids on serum cystatin C in identifying acute kidney injury: a propensity-matched cohort study. BMC Nephrol. 2020;21(1):519.","journal-title":"BMC Nephrol"},{"issue":"6","key":"1618_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2008.638","volume":"75","author":"LA Stevens","year":"2009","unstructured":"Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75(6):652\u201360.","journal-title":"Kidney Int"},{"key":"1618_CR32","volume":"2018","author":"JN Barreto","year":"2018","unstructured":"Barreto JN, McClanahan AL, Rule AD, et al. Incorporating cystatin C to predict methotrexate elimination in patients with CNS lymphoma and suspicious renal function. Case Rep Hematol. 2018;2018:7169897.","journal-title":"Case Rep Hematol"},{"issue":"1","key":"1618_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cts.13125","volume":"15","author":"JN Barreto","year":"2022","unstructured":"Barreto JN, Reid JM, Thompson CA, et al. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. Clin Transl Sci. 2022;15(1):105\u201317.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1618_CR34","first-page":"1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1\u2013138.","journal-title":"Kidney Int Suppl"},{"issue":"25","key":"1618_CR35","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1618_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0021-9681(72)90027-6","volume":"25","author":"A Keys","year":"1972","unstructured":"Keys A, Fidanza F, Karvonen MJ, et al. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6):329\u201343.","journal-title":"J Chronic Dis"},{"issue":"4","key":"1618_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/phar.2379","volume":"40","author":"MP Pai","year":"2020","unstructured":"Pai MP, Debacker KC, Derstine B, et al. Comparison of body size, morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary central nervous system lymphoma. Pharmacotherapy. 2020;40(4):308\u201319.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1618_CR38","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M, et al. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019;84(6):1339\u201348.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1618_CR39","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bcp.15506","volume":"89","author":"M Ibarra","year":"2023","unstructured":"Ibarra M, Combs R, Taylor ZL, et al. Insights from a pharmacometric analysis of HDMTX in adults with cancer: clinically relevant covariates for application in precision dosing. Br J Clin Pharmacol. 2023;89(2):660\u201371.","journal-title":"Br J Clin Pharmacol"},{"key":"1618_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.817673","volume":"13","author":"J Mao","year":"2022","unstructured":"Mao J, Li Q, Li P, et al. Evaluation and application of population pharmacokinetic models for identifying delayed methotrexate elimination in patients with primary central nervous system lymphoma. Front Pharmacol. 2022;13:817673.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1618_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","volume":"108","author":"ZL Taylor","year":"2020","unstructured":"Taylor ZL, Mizuno T, Punt NC, et al. MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. Clin Pharmacol Ther. 2020;108(3):635\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1618_CR42","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/cts.13600","volume":"16","author":"ZL Taylor","year":"2023","unstructured":"Taylor ZL, Miller TP, Poweleit EA, et al. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci. 2023;16(11):2130\u201343.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1618_CR43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2759","volume":"38","author":"I Amitai","year":"2020","unstructured":"Amitai I, Rozovski U, El-Saleh R, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol. 2020;38(4):584\u20138.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1618_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43046-022-00122-7","volume":"34","author":"S Barakat","year":"2022","unstructured":"Barakat S, Assem H, Salama M, et al. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia? J Egypt Natl Cancer Inst. 2022;34(1):17.","journal-title":"J Egypt Natl Cancer Inst."},{"issue":"12","key":"1618_CR45","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/pbc.25137","volume":"61","author":"E Ylinen","year":"2014","unstructured":"Ylinen E, Jahnukainen K, Saarinen-Pihkala UM, et al. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(12):2199\u2013202.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"1618_CR46","first-page":"5293","volume":"29","author":"JN Barreto","year":"2021","unstructured":"Barreto JN, Peterson KT, Barreto EF, et al. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Support Care Cancer. 2021;29(9):5293\u2013301.","journal-title":"Support Care Cancer"},{"issue":"10","key":"1618_CR47","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.34067\/KID.0003202022","volume":"3","author":"DC Chen","year":"2022","unstructured":"Chen DC, Potok OA, Rifkin D, et al. Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR. Kidney360. 2022;3(10):1807\u201314.","journal-title":"Kidney360"},{"issue":"3","key":"1618_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","volume":"62","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013;62(3):595\u2013603.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1618_CR49","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382.","journal-title":"Oncologist"},{"issue":"12","key":"1618_CR50","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1111\/jcpt.13791","volume":"47","author":"K Sun","year":"2022","unstructured":"Sun K, Tao H, Ding T, et al. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma. J Clin Pharm Ther. 2022;47(12):2196\u2013204.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1618_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/phar.2889","volume":"44","author":"ML Rice","year":"2024","unstructured":"Rice ML, Barreto EF, Rule AD, et al. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma. Pharmacotherapy. 2024;44(1):4\u201312.","journal-title":"Pharmacotherapy"},{"issue":"16","key":"1618_CR52","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2021014506","volume":"139","author":"MR Wilson","year":"2022","unstructured":"Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139(16):2499\u2013511.","journal-title":"Blood"},{"issue":"S2","key":"1618_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hon.3164_244","volume":"41","author":"JT Shreve","year":"2023","unstructured":"Shreve JT, Hazim AZ, Bock AM, et al. Automated FDG PET\/CT radiomics for risk stratification in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Hematol Oncol. 2023;41(S2):341\u20132.","journal-title":"Hematol Oncol"},{"key":"1618_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1193494","volume":"3","author":"RK Buddington","year":"2023","unstructured":"Buddington RK, Wong T, Buddington KK, et al. Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs. Front Nephrol. 2023;3:1193494.","journal-title":"Front Nephrol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01618-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:02:30Z","timestamp":1772640150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01618-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01618-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was conducted in the absence of a competing interest or financial relationship; however, the authors report the following: Zachary L. Taylor and Laura B. Ramsey have received research funding from SERB Pharmaceuticals. Erin F. Barreto serves in a consulting or advisory role for Wolters-Kluwer and Baxter-Health. Erin F. Barreto has received research funding from Numares AG. Andrew D. Rule receives royalties from UpToDate. Nelson Leung has stock or ownership interests in Senseonics, AbbVie, Verrica Pharmaceuticals, and Checkpoint Therapeutics. Nelson Leung has received research funding from Omeros. Thomas E. Witzig has received honoraria, from Curio Science, serves in a consulting or advisory rolefor Tornado Therapeutics and Salarius Pharmaceuticals, and has received research funding fromCelgene, Acerta Pharma, Kura Oncology, Acrotech Biopharma, and Karyopharm Therapeutics. Jason N. Barreto serves in a consulting or advisory role for Optum, and has received research funding from Asellas Pharma and Numares AG. Kristin C. Cole, Kianoush B. Kashani, and Carrie A. Thompson have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This prospective single-center study was conducted in accordance with Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. The protocol was reviewed and approved by the Mayo Clinic Institutional Review Board (ID: 17-007837). Patient confidentiality was maintained in compliance with the US Health Insurance Portability and Accountability Act.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior to enrollment in accordance with the protocol that was approved by the Mayo Clinic Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of their data at the time of study enrollment, as part of the informed consent process.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets that support the findings of this study are not publicly available because of institutional privacy policies but may be made available from the corresponding author upon reasonable request and with appropriate data use agreements.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Population PK modeling was performed using NONMEM (Version 7.5) with Pirana and Perl-speaks-NONMEM (PsN) workbench tools. No custom code was developed for this study beyond standard model scripting within these platforms. Model scripts may be made available upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ZLT, EFB, KMC, ADR, KBK, NL, CAT, TEW, LBR, and JNB contributed to the conception and design of the research. ZLT, EFB, KMC, and JNB performed the research. ZLT, EFB, KMC, ADR, KBK, CAT, TEW, LBR, and JNB analyzed the data. All authors contributed to the drafting and critical revision of the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}